{"id":864496,"date":"2025-06-27T06:53:07","date_gmt":"2025-06-27T10:53:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\/"},"modified":"2025-06-27T06:53:07","modified_gmt":"2025-06-27T10:53:07","slug":"pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\/","title":{"rendered":"Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">ZUG, Switzerland, June  27, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7fhjNk53Rnioi33xanHv8K4rguaWPagaWmqyy4u9HGr0AOq8CY4aL2Zx5m8U6C9aL7WClquXK836Xio_qHs2Ug==\" rel=\"nofollow\" target=\"_blank\">Pharvaris<\/a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Association&#8217;s 2025 National Summit to be held from July 10-13, 2025, in Baltimore, Maryland.<\/p>\n<p>Details of the presentations are as follows:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Title: <\/strong>Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study\u00a0<br \/><strong>Presenter: <\/strong>Michael E. Manning, M.D.<br \/><strong>Format: <\/strong>Poster Presentation, #22<br \/><strong>Date, time: <\/strong>Friday, July 11, 12:30-13:30 ET<\/li>\n<li>\n          <strong>Title: <\/strong>Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study<br \/><strong>Presenter: <\/strong>Michael E. Manning, M.D.<br \/><strong>Format: <\/strong>Poster Presentation, #20<br \/><strong>Date, time: <\/strong>Friday, July 11, 12:30-13:30 ET<\/li>\n<li>\n          <strong>Title: <\/strong>CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks<br \/><strong>Presenter:<\/strong> H. Henry Li, M.D., Ph.D.<br \/><strong>Format: <\/strong>Poster Presentation, #5<br \/><strong>Date, time:<\/strong> Friday, July 11, 12:30-13:30 ET<\/li>\n<li>\n          <strong>Title: <\/strong>Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study<br \/><strong>Presenter: <\/strong>Marc A. Riedl, M.D., M.S.<br \/><strong>Format: <\/strong>Poster Presentation, #23<br \/><strong>Date, time:<\/strong> Friday, July 11, 12:30-13:30 ET<\/li>\n<li>\n          <strong>Title:<\/strong> Durability of response to a single dose of oral deucrictibant for on-demand treatment of hereditary angioedema attacks<br \/><strong>Presenter:<\/strong> Joshua S. Jacobs, M.D.<br \/><strong>Format: <\/strong>Poster Presentation, #9<br \/><strong>Date, time:<\/strong> Friday, July 11, 12:30-13:30 ET<\/li>\n<li>\n          <strong>Title: <\/strong>Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched Analysis<br \/><strong>Presenter: <\/strong>Mark D. Scarupa, M.D. <br \/><strong>Format: <\/strong>Poster Presentation, #7<br \/><strong>Date, time:<\/strong> Friday, July 11, 12:30-13:30 ET<\/li>\n<\/ul>\n<p>The posters will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RET-TG1PWiy2NiFSEMit_h6MtX6R3GgvOGbREnvMUy6dmrVU1TxX9ee3vgJOCFSVEtcVCgSYU4SYmCsR0ez-nEnvQoa9EzTf1N0OMpeOCALIj5MsLDJNtIQpatHL2_hynva-O4IY-WuBtVt_QhOW35NdZ_saY15uVZf5H8AVRoLkU-PSVALdnBcPd03rg3Xg1Pr1gbutN2-_kin_uBWNQK6-iTDsHvsSh3RFZVDHohmUvIzo2V_br0JVNx6RDi_byis_Aai06ecvC_GXpYv9pM_5aDAda-rKO_ta-zB-C3cVcBVe-kjO55MFZc_erI5Ca83kPjEZpNCu6mkJtqMrwGuKgySsXTlvef3EeqPwUw_WtyiUv67tsvIiFYB9ENU6pUA9XEquYtJetnNttDpKEVNdaleavyDrIsybvxFTRX4=\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.pharvaris.com\/news-events\/events-presentations<\/a>.<\/p>\n<p>\n        <strong>About Pharvaris<\/strong><br \/>\n        <br \/>Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy\u2122 and placebo-like tolerability with the convenience of oral therapies to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RET-TG1PWiy2NiFSEMit_on2sNTF8iPtdoLR_kBYdfEYXjaGayEyyfM2uQ1fMS4OeYhU1IV98SgdTopIbfhNBh0QXs2SwPBU5nYY8F51GlzFehkejcJpnlswC7oydk4guTqOIE3tp1sV1mt7Ldtye_IdN-ho_xwmIg-QwYObGLn8ppegdGYIFgKkFkVFl8dZyq9N8XOCFJ2JDqH29mWLXyElf51XKUFqgpwQ4eQkaE8CJo6hYSLwepPNgd3szUU9QunWNudd72mvapVNEZXFhV_utJTxuWvSgq9yxw3OTina35N3f3u5dvK8sfwYYaY9ACbcXsu1k5nNCeXvbRLyunmgLeZMYpsy8HNa30w-jsYcVgWuDEhxWwSaxy4PAl4TMOuQaIDf7yt8rTFYkM3qDcjBSz1eiQ39UkL4UZHsmLlsr2C_dstetrD0v4S0hIYXpJTR-gGKstir_405PuUqdNYaSSoOl_leqkctVWoTAxeStrVvFO9bCFVQOzVVmHBz7JQP13U_7x3XLFBxFqKnedfSSO9LvhZDKB3OKGGZgMHUxLvKJ2N5cJZ1TuZHSDRnVQDnm4vOeEM4j4ym9X_wr1zjVh6vffqTlRK7IgZ637Fj4qrjF8NPQD7R0gnCxkpI-ODE0oeFEahH-u7ipLaqlW6ylnqJdSyHEDyFyOfn2u46kxLsaRpe4rraYd8tmaviyknfOqgWMlOC6UgozG35TKDNiJtTAdm7zoaEr8Q5g6K6T3RqDg1Winjq493McmckuYDzc1x9wWfz19M7aXldF66pvKDyPfVFhUJmGBeVbHSJhN-L5PGIneQu36dnzkdZGfBfIHi8CR3h56ZC8zx2tl4LLP86tKJPrj0HpisDaje463nkbEJiFqjWnxXn2uh3bG8OeNQanbTNOjpldA9OVhZBQ-dhEh10usNSLoQNubaI-l-dbOxyrYAyBYMYEfBlnFLunxxfNj2Tgz17HJh_g5olpeaskI0_8oa-OcGKBL02ojTbat0rRgBUYckJMoGW6Lh6izuD1oVKpOtV8vZSJtsq8W-QmBWTWj4CbP3nKxD_oCxdhN6ZA_ynEtSJC8Y9cD1agQ0sI2tt_VuBGakB_SMrMjOha3HrKfR4gFz1YLXj05Pmquk7tGEZKAMWVywaY4vHaQJJvfNye6hXyUBVsYUWy_Co0KM1E2w_HcKUhfiDl1ZCHkZIARsMviiip6-rNCb6vtFE5flQVYhZItq9qN_CMk5oOWrTD8U4LF3r3sflKtZjs80g5C0gZ-xoIoTBjRC0HmY4g6xKubVn52LMraGtAiaAal40L2C9xT35NAmI6tup6uhZ1buPzWTWefYrrQdTpr1KffG99eWQ4Wh6avgPN8sOY5jeCVTN-zTJJBXaDAdxe0AErmx0NuVe4ROIpLcaRdnZ6Kj7f08K6p2hSnyl1T0x5PJIlvuu0YtWeaE-umuuqv9rsrnYMzNtt0zi__88cl5Qfhn1LnfBdw7Vhwu7sbVkX2LUZj2Jg-AoMBmxrLvGeWof7G9pqu2QDfvsn7Qo1ymNPb9j54OYwqRRVK-nUUQC52sOc4qbGo3md9diODecrQIg6rA2ecOWuYnWD9_kjlLDb_FW3KyVyiE1S1xpb2_yuGKBu2tcPL-DLWIhDANR3BPrBG9T4afH7WB8y6k88n7_s1GEclPOYqzN3ggyYN8bGPQgcnyKl_1TfsjXE42j8-awF9OscBVXVPnDVB97n_-JeEveX7j-opxq9w==\" rel=\"nofollow\" target=\"_blank\">https:\/\/pharvaris.com\/<\/a>.<\/p>\n<p>\n        <strong>Contact <\/strong><br \/>\n        <br \/>Maggie Beller <br \/>Executive Director, Head of Corporate and Investor Communications <br \/>maggie.beller@pharvaris.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NTUyMyM3MDIxMjk3IzIyMDU5NDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmYxODc5MDAtYzc3MS00ZjAyLWEwYWYtNGRjMmU1MDU2NDYwLTEyMTc1MDAtMjAyNS0wNi0yNy1lbg==\/tiny\/Pharvaris-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) &#8212; Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Association&#8217;s 2025 National Summit to be held from July 10-13, 2025, in Baltimore, Maryland. Details of the presentations are as follows: Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study\u00a0Presenter: Michael E. Manning, M.D.Format: Poster Presentation, #22Date, time: Friday, July 11, 12:30-13:30 ET Title: Long-Term Prophylactic Treatment &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-864496","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) &#8212; Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Association&#8217;s 2025 National Summit to be held from July 10-13, 2025, in Baltimore, Maryland. Details of the presentations are as follows: Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study\u00a0Presenter: Michael E. Manning, M.D.Format: Poster Presentation, #22Date, time: Friday, July 11, 12:30-13:30 ET Title: Long-Term Prophylactic Treatment &hellip; Continue reading &quot;Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-27T10:53:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NTUyMyM3MDIxMjk3IzIyMDU5NDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit\",\"datePublished\":\"2025-06-27T10:53:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\\\/\"},\"wordCount\":456,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4NTUyMyM3MDIxMjk3IzIyMDU5NDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\\\/\",\"name\":\"Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4NTUyMyM3MDIxMjk3IzIyMDU5NDc=\",\"datePublished\":\"2025-06-27T10:53:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4NTUyMyM3MDIxMjk3IzIyMDU5NDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4NTUyMyM3MDIxMjk3IzIyMDU5NDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\/","og_locale":"en_US","og_type":"article","og_title":"Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit - Market Newsdesk","og_description":"ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) &#8212; Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Association&#8217;s 2025 National Summit to be held from July 10-13, 2025, in Baltimore, Maryland. Details of the presentations are as follows: Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study\u00a0Presenter: Michael E. Manning, M.D.Format: Poster Presentation, #22Date, time: Friday, July 11, 12:30-13:30 ET Title: Long-Term Prophylactic Treatment &hellip; Continue reading \"Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-27T10:53:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NTUyMyM3MDIxMjk3IzIyMDU5NDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit","datePublished":"2025-06-27T10:53:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\/"},"wordCount":456,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NTUyMyM3MDIxMjk3IzIyMDU5NDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\/","name":"Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NTUyMyM3MDIxMjk3IzIyMDU5NDc=","datePublished":"2025-06-27T10:53:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NTUyMyM3MDIxMjk3IzIyMDU5NDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NTUyMyM3MDIxMjk3IzIyMDU5NDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-presented-at-the-2025-us-haea-national-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/864496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=864496"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/864496\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=864496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=864496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=864496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}